Zhan-Guo Gao, Mansour Haddad, and Kenneth A Jacobson for their work on A2B adenosine receptor signaling

Terry’s Corner: Why Binding Kinetics Matter More Than Affinity In drug discovery today, time wasted is interpret kinetic binding experiments and recognize when a drug’s rate of onset and offset matter more than

When complexity grows faster than strategy, biotech companies begin to fall apart quietly. 👉 This article When complexity grows faster than clarity 👉 Early-stage biotech is complex by default. The problem begins when they expand faster than the company’s ability to make clear decisions. More experiments feel safer than fewer deliberate ones.   Scientists trust leadership because decisions are grounded in logic rather than mood.

Elva Zhao on biased agonism at the GLP-1 receptor, G protein regulation, and building a mechanistic picture of GPCR pharmacology from the inside out. << Back to podcast list Strategic Partner(s) Elva Zhao: G Elva Zhao brings an unusual vantage point to that question. The connection runs deeper than science: Zhao's grandmother worked as a pharmacologist on diabetes in Elva Zhao on the web LinkedIn Monash University Pubmed Twitter Dr.

She argues that the field has moved faster than the evidence warrants: approving antibodies and small across academia, big pharma, and biotech KEY INSIGHTS FROM THE CONVERSATION Fifteen Genes, Far More Than and fine-grained, not structurally obvious, making ligand selectivity considerably harder to engineer than feel less pain from those setbacks, but the ones for whom the pull toward the question is stronger than the picture 11:03 Class B GPCRs - why 15 receptor genes produce far greater pharmacological diversity than

Foord is a physiologist and pharmacologist who spent more than two decades at Glaxo, Glaxo Wellcome, combined with highly sensitive cAMP readouts in Xenopus oocytes, unexpectedly pulled out RAMP1 rather than Target Validation Is Harder Than Cloning a Receptor . artifacts, underscoring that robust target validation is a distinct and often more challenging problem than shaped the fate of the EP4 partial agonist that ultimately found a niche in veterinary medicine rather than